Shots:

• ACEA to receive up to ~$38M in shares of Sorrento common stock- $450M as additional payments upon the achievement of clinical & sales milestones along with 5 – 10% royalties based on annual sales of each product. The acquisition is expected to close in Q2’ 21
• The acquisition includes Abivertinib- AC0058- AC0939- and ACEA’s compound library of small molecules which has the potential for numerous human disease indications- including NSCLC- BCL- SL- RA- MS and viral infections
• The acquisition will also include ACEA’s state of the art cGMP facility located in Quzhou- China which has the capacity to manufacture up to 5-000 kg/year of APIs and 50-000-000 capsules of final drug product

  Ref: GlobeNewswire | Image: Biocom